Redeployed drug inducing MLL fusion degradation

Introduction: Acute leukemias in infants are quite rare but generate a great interest due to the aggressive clinical features. The survival rate for these infants is less than 50%. The vast majority of infant acute leukemias are characterized cytogenetically by balanced chromosomal translocations involving the mixed lineage leukemia (MLL) gene. Leukemic therapies that degrade the driver oncogene are associated with loss of cancer cell self-renewal and excellent cure rates. Therefore, therapy that degrades the MLL fusion gene would offer new hope to these patients. Developing a brand new drug takes a big amount o…